A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer

NCT05656092 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2025-02-19

No results posted yet for this study

Summary

A multicenter, randomized, double-blind, active-controlled, phase III study to evaluate the efficacy and safety of HIP0612 in patients with gastric ulcer.

Conditions

  • Gastric Ulcer

Interventions

DRUG

HIP0612

Test drug

DRUG

HPP2202

Placebo drug

DRUG

RLD2204

Reference drug

DRUG

HPP2201

Placebo drug

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2024-12-19
Completion
2024-12-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05656092 on ClinicalTrials.gov